NasdaqGS - Delayed Quote USD

InflaRx N.V. (IFRX)

1.3300 -0.0600 (-4.32%)
At close: April 26 at 4:00 PM EDT
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
63.0890
63.0890
--
--
--
Cost of Revenue
532.2620
532.2620
--
--
--
Gross Profit
-469.1730
-469.1730
--
--
--
Operating Expense
44,438.9220
44,438.9220
32,237.8660
47,634.8170
33,942.8040
Operating Income
-44,908.0950
-44,908.0950
-32,237.8660
-47,634.8170
-33,942.8040
Net Non Operating Interest Income Expense
4,082.4390
4,082.4390
310.9580
40.6220
735.7020
Other Income Expense
-1,841.8720
-1,841.8720
2,442.2970
1,964.1350
-776.5120
Pretax Income
-42,667.5280
-42,667.5280
-29,484.6110
-45,630.0600
-33,983.6140
Net Income Common Stockholders
-42,667.5290
-42,667.5290
-29,484.6110
-45,630.0590
-33,983.6140
Diluted NI Available to Com Stockholders
-42,667.5290
-42,667.5290
-29,484.6110
-45,630.0590
-33,983.6140
Basic EPS
-0.68
-0.78
-0.67
-1.10
-1.26
Diluted EPS
-0.68
-0.78
-0.67
-1.10
-1.26
Basic Average Shares
51,253.9960
54,940.1370
44,207.8730
41,629.9740
27,064.9020
Diluted Average Shares
51,253.9960
54,940.1370
44,207.8730
41,629.9740
27,064.9020
Total Operating Income as Reported
-44,908.0960
-44,908.0960
-32,237.8660
-47,634.8170
-33,942.8040
Total Expenses
44,971.1840
44,971.1840
32,237.8660
47,634.8170
33,942.8040
Net Income from Continuing & Discontinued Operation
-42,667.5290
-42,667.5290
-29,484.6110
-45,630.0590
-33,983.6140
Normalized Income
-40,825.6570
-40,825.6570
-31,926.9080
-47,594.1940
-33,207.1020
Interest Income
3,804.8270
3,804.8270
608.6790
109.3910
887.7020
Interest Expense
35.6280
35.6280
45.2500
24.7690
26.0000
Net Interest Income
4,082.4390
4,082.4390
310.9580
40.6220
735.7020
EBIT
-42,631.9000
-42,631.9000
-29,439.3610
-45,605.2910
-33,957.6140
EBITDA
-42,064.1200
-42,064.1200
-28,842.7640
-44,935.8570
-33,244.9010
Reconciled Cost of Revenue
472.3870
472.3870
--
--
--
Reconciled Depreciation
567.7800
567.7800
596.5970
669.4340
712.7130
Net Income from Continuing Operation Net Minority Interest
-42,667.5290
-42,667.5290
-29,484.6110
-45,630.0590
-33,983.6140
Total Unusual Items Excluding Goodwill
-1,841.8720
-1,841.8720
2,442.2970
1,964.1350
-776.5120
Total Unusual Items
-1,841.8720
-1,841.8720
2,442.2970
1,964.1350
-776.5120
Normalized EBITDA
-40,222.2480
-40,222.2480
-31,285.0610
-46,899.9920
-32,468.3890
12/31/2020 - 11/7/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CMMB Chemomab Therapeutics Ltd.
0.6399
-2.90%
 
MIRM Mirum Pharmaceuticals, Inc.
24.46
-0.12%
 
ZYME Zymeworks Inc.
8.26
+1.85%
 
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
 
ACHL Achilles Therapeutics plc
0.7600
-2.69%
 
GLTO Galecto, Inc.
0.7048
+5.62%
 
APVO Aptevo Therapeutics Inc.
0.7061
+3.84%
 
NEXI NexImmune, Inc.
3.3700
-1.17%
 
GBIO Generation Bio Co.
2.9000
-3.65%
 
PYPD PolyPid Ltd.
4.7525
+4.45%